About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.655 -0.045 (-2.65%)
Streaming Delayed Price Updated: 12:49 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 517,715
Open 1.680
Bid (Size) 1.650 (1,500)
Ask (Size) 1.660 (6,400)
Prev. Close 1.700
Today's Range 1.630 - 1.720
52wk Range 0.7100 - 1.890
Shares Outstanding 116,236,018
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Coherus Oncology, Inc.
Via GlobeNewswire

Performance

YTD
+20.8%
+20.8%
1 Month
+19.1%
+19.1%
3 Month
-2.6%
-2.6%
6 Month
+94.8%
+94.8%
1 Year
+12.6%
+12.6%

More News

Read More
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Coherus BioSciences's Earnings Outlook ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Insights Ahead: Coherus BioSciences's Quarterly Earnings ↗
Via Benzinga
News headline image
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
Via Benzinga
News headline image
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
Via Benzinga
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus (CHRS) Q2 Revenue Jumps 10% ↗
Via The Motley Fool
News headline image
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Friday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Top movers in Friday's after hours session ↗
Via Chartmill
News headline image
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill

Frequently Asked Questions

Is Coherus Oncology, Inc. - Common Stock publicly traded?
Yes, Coherus Oncology, Inc. - Common Stock is publicly traded.
What exchange does Coherus Oncology, Inc. - Common Stock trade on?
Coherus Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Coherus Oncology, Inc. - Common Stock?
The ticker symbol for Coherus Oncology, Inc. - Common Stock is CHRS on the Nasdaq Stock Market
What is the current price of Coherus Oncology, Inc. - Common Stock?
The current price of Coherus Oncology, Inc. - Common Stock is 1.655
When was Coherus Oncology, Inc. - Common Stock last traded?
The last trade of Coherus Oncology, Inc. - Common Stock was at 01/14/26 12:49 PM ET
What is the market capitalization of Coherus Oncology, Inc. - Common Stock?
The market capitalization of Coherus Oncology, Inc. - Common Stock is 192.37M
How many shares of Coherus Oncology, Inc. - Common Stock are outstanding?
Coherus Oncology, Inc. - Common Stock has 192M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.